Banz et al. [35]
|
15 months; 11–12 years
|
86 %
|
0.5 %
|
85 % (children); 30 % (adolescents)
|
EUR 65.93 (children)a; EUR 71.38 (adolescents)a
|
Banz et al. [51]
|
1-2 years; 11–15 years
|
95 %
|
0.5 %
|
70 % (children); 85 % (adolescents)
|
EUR 42.20 (children)a; EUR 56.65 (adolescents)a
|
Beutels et al. [37]
|
15 months; 12 years
|
90 %
|
Waning in 15 % of the protected vaccineesb
|
70 %
|
EUR 50.82a
|
Bilcke et al. [30]
|
1 year (1st dose); 4, 6 or 11 years (2nd dose)
|
Data from van Hoek et al. 2012
|
Data from van Hoek et al. 2012
|
50 % or 95 % (1st dose); 50 %, 80 % or 90 % (2nd dose)
|
EUR 44.92a
|
Bonanni et al. [36]
|
12-18 months; 13 years
|
90 % (1st dose); 93 % (2nd dose)
|
3 %
|
85 %
|
EUR 46.81a,c
|
Brisson et al. [31]
|
12 months; 12 years
|
93 %
|
3.1 %
|
90 % (infants); 80 % (adolescents)
|
EUR 51.42 (children)a; EUR 68.57 (adolescents)a
|
Brisson et al. [32]
|
Infants; 11 years
|
93 %
|
3.1 %
|
90 % (infants); 80 % (adolescents)
|
EUR 44.32 (children)a; EUR 59.10 (adolescents)a
|
Coudeville et al. [52]
|
<6 years
|
90 %
|
Waning in 15 % of the protected vaccineesb
|
80 %
|
EUR 18.11c,d
|
Coudeville et al. [53]
|
12-36 months
|
97 %
|
3.1 %
|
45 %-90 %
|
EUR 52.00a,c
|
Coudeville et al. [54]
|
12-36 months
|
97 %
|
3.1 %
|
45 %-90 %
|
EUR 64.08 (Germany)a,c; EUR 59.56 (France)a,c
|
Diez Domingo et al. [55]
|
15 months
|
90 %
|
No waning
|
95 %
|
EUR 37.11
|
Getsios et al. [56]
|
12 months
|
90 %
|
Waning in 15 % of the protected vaccineesb
|
85 %
|
EUR 60.25a,d
|
Ginsberg & Somekh [57]
|
12 months
|
87.6 %
|
3.1 %
|
94 %
|
EUR 8.01a,c,d
|
Hammerschmidt et al. [58]
|
11-23 months (catch-up of 2–17 year olds)
|
86 % (1-dose schedule); 95 % (2-dose schedule)
|
0.5 %
|
90 % (1st dose); 80 % (2nd dose); 30 % (catch-up); 10 % (comparator)
|
EUR 47.38 (monovalent vaccine); EUR 47.92 (varicella-attributable cost of the MMRV vaccine)
|
Huse et al. [59]
|
15 months
|
95 %
|
No waning
|
Not specified
|
EUR 62.31a
|
Lenne et al. [60]
|
1-2 years
|
97 %
|
3,1 %
|
97,15 %
|
EUR 42.54a
|
Lieu et al. [61]
|
<6 years
|
90 %
|
Waning in 15 % of the protected vaccineesb
|
97 %
|
EUR 54.12a
|
Preblud et al. [62]
|
15 months
|
90 %
|
No waning
|
90 %
|
EUR 25.53
|
Scuffham et al. [63]
|
15 months
|
95 %
|
No waning
|
80 %; 10 % (comparator)
|
EUR 45.94
|
Scuffham et al. [34]
|
12 months; 12 years
|
95 %
|
No waning
|
80 % (infants); 50-75 % (adolescents)
|
EUR 42.26
|
Thiry et al. [64]
|
11 years
|
93,12 %
|
3.1 %
|
60 %
|
EUR 52.36a
|
van Hoek et al. [33]
|
1 year (1st dose); 3 years (2nd dose)
|
89-96 % (1st dose); 93-96 % (2nd dose)
|
1.5-6.7 % (1st dose); 0.05-2.6 % (2nd dose)
|
90 % (1st dose); 80 % (2nd dose)
|
EUR 41.19
|
Zhou et al. [29]
|
Children
|
80 % (1-dose schedule)e; 93 % (2-dose schedule)
|
No waning
|
Age-specific coverage rates; 95 % (2nd dose)
|
EUR 49.90 (monovalent vaccine)f; EUR 65.64 (MMRV vaccine)f
|